TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07896941: A Clinical Trial to Evaluate the Safety and Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cell (CG-BM1) Injection in the Treatment of Ischemic Stroke

Sponsor: GuangZhou Cellgenes Biotechnology Co., Ltd. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 87 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT07896941 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07896941 Rescue Dossier →